Science Abstracts
Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?
September 2010
September 2010
Authors : Darrell H Carney , Barbara Olszewska-Pazdrak
Affliation : The University of Texas Medical Branch, Therapeutic Peptide Development Laboratory, Department of Biochemistry and Molecular Biology, 301 University Blvd, Galveston, TX 77555-0647, USA ; ; dcarney@utmb.edu
DOI : 10.1517/14656566.0.0.340340
Published in : Expert Opin. Pharmacother.
Subject: Drug Evaluation
Keywords: angiogenesis , chronic wounds , diabetic foot ulcers , endothelial dysfunction , fracture repair , osteoporosis , rusalatide acetate
Abstract
Rusalatide acetate (Chrysalin ®)...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA advisors vote to stop Avastin as breast cancer therapy
- Genmab's zalutumumab fails Phase III trial in refractory head and neck cancer
- FDA hands refusal to file letter to EpiCept for lead leukaemia product
- US FDA gives green light to Rockwell's Phase III iron replacement therapy programme
FEATURES
- Connexios: Harnessing the Indian cost advantage in network biology
- GE Healthcare aims to end unpredictability in early drug research
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
